Exelan Pharmaceuticals Inc.

Exelan Pharmaceuticals Inc. Exelan Pharmaceuticals Division, a foreign-owned for-profit pharmaceutical manufacturer and distributor headquartered in Boca Raton, Florida, supplies generic and branded pharmaceutical products and repackaging services to federal healthcare systems as a prime contractor on an unrestricted, fully open competitive basis with no set-aside designations. The company competes across 100% prime awards spanning 216 federal contract vehicles and has accumulated $4.36 billion in combined potential value across recent awards, with $195.3 million obligated to date.

Exelan's capability portfolio centers on bulk pharmaceutical manufacturing, distribution, and repackaging into patient-ready prescriptions for multiple therapeutic categories. Representative work includes a $88.2 million single-award indefinite-delivery contract with the Department of Veterans Affairs National Acquisition Center for Tamsulosin Hydrochloride 0.4 mg capsules (awarded September 2025), a $63.1 million IDC for Diclofenac Sodium 1% topical gel (September 2025), a $48.4 million IDC for Escitalopram Oxalate tablets across three strengths (March 2024), a $40.5 million IDC for Lisinopril tablets in 23 strength/package combinations (February 2022), a $29.9 million IDC for Nicotine 24-hour transdermal patches (February 2026), and a $74.1 million delivery order from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response for Oseltamivir Phosphate 75 mg and 30 mg capsules (June 2025). The company also operates an ongoing $21.2 million blanket purchase agreement with Veterans Integrated Service Network 22 for Lenalidomide supply supporting oncology treatment protocols, against which nine BPA calls totaling $18.7 million have been issued.

Customer concentration is extreme and skewed toward VA components. Veterans Integrated Service Network 12 alone anchors the portfolio with 14 awards carrying $3.1 billion in combined potential value—roughly 71% of total portfolio dollars. The Department of Veterans Affairs National Acquisition Center places the most awards by count (105 awards, $757.7 million combined potential value), while Defense Logistics Agency Troop Support Medical ranks third with 15 awards worth $289.9 million. Together, these three customers account for 98% of combined potential value across the 20 distinct agencies served. Activity has accelerated sharply: eight awards in 2022 climbing to 47 in 2026 year-to-date. Awards reaching ultimate completion within the next twenty-four months total 50 vehicles with combined potential value of $179.6 million, representing significant recompete exposure.

Exelan holds or operates under two parent vehicle frameworks. The Pharmaceuticals and Drugs GSA Federal Supply Schedule (FSS-61-IB) anchors the portfolio with 185 delivery orders totaling $231.7 million in combined potential value—the primary contract vehicle for task orders across VA, Defense, Bureau of Prisons, and Indian Health Service. An estimated multi-billion-dollar ceiling Federal Supply Schedule contract is referenced across multiple award summaries as the parent procurement framework. Exelan also holds numerous single-award indefinite-delivery contracts directly with the Department of Veterans Affairs National Acquisition Center and Defense Logistics Agency spanning more than twenty pharmaceutical products across therapeutic categories including cardiovascular agents, anticonvulsants, pain management, antiviral, gastrointestinal, and hematologic/oncology medications, with individual IDC ceilings ranging from $4.2 million to $88.2 million. The company operates as a prime contractor exclusively; no subcontractors are identified across the award portfolio.

Category concentration is absolute: 207 of 216 awards fall under NAICS code 325412 (Pharmaceutical Preparation Manufacturing), and 209 awards carry PSC code 6505 (Drugs and Biologicals). Exelan performs substantially all work at its primary Boca Raton, Florida manufacturing and distribution facility, with secondary performance locations in Cary, North Carolina; Summit, New Jersey; Ottawa, Ontario, Canada; and other designated federal delivery locations as specified by contracting agencies. The company maintains active System for Award Management registration and has incorporated approved subcontracting plans into recent contract awards, including 2026/2027 and 2027 cycles. Recent award activity dates from October 2026; the company's federal supply schedule contract ceiling appears to expire September 14, 2025, though subsequent delivery orders continue to flow against it, suggesting potential amendment or renewal.